MAOYAN ENT (01896) · Company profile · Eqvero

MAOYAN ENT

01896HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	4.63 bn CNY	4.08 bn CNY	4.76 bn CNY	2.32 bn CNY	3.32 bn CNY
Cost of revenue	2.52 bn CNY	2.33 bn CNY	2.25 bn CNY	1.15 bn CNY	1.31 bn CNY
Research and development expense	201.39 m CNY	218.96 m CNY	215.41 m CNY	195.63 m CNY	229.89 m CNY
Selling, general and administrative expense	1.23 bn CNY	1.3 bn CNY	1.21 bn CNY	780.06 m CNY	1.03 bn CNY
Operating profit after depreciation	824 m CNY	257.3 m CNY	1.1 bn CNY	225.23 m CNY	787.3 m CNY
Operating profit before depreciation	935.26 m CNY	387.6 m CNY	1.23 bn CNY	374.45 m CNY	958.24 m CNY
EBIT	824 m CNY	257.3 m CNY	1.1 bn CNY	225.23 m CNY	787.3 m CNY
EBITDA	935.26 m CNY	387.6 m CNY	1.23 bn CNY	374.45 m CNY	958.24 m CNY
Interest expense	10.09 m CNY	9.55 m CNY	5.12 m CNY	17.14 m CNY	31.29 m CNY
Profit before tax	774.78 m CNY	301.33 m CNY	1.15 bn CNY	181.29 m CNY	534.84 m CNY
Income tax expense	211.69 m CNY	119.42 m CNY	245.84 m CNY	76.48 m CNY	166.34 m CNY
Income before extraordinary items	563.65 m CNY	181.91 m CNY	910.41 m CNY	105.19 m CNY	368.5 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.